Reaction Biology Europe GmbH is a 100% subsidiary of Reaction Biology Corporation (Malvern/PA, USA), based in Freiburg im Breisgau, and provides products and services in preclinical drug research, with a focus on oncology. The portfolio is explicitly divided into (i) production and sale of recombinant proteins and (ii) execution of in vitro and in vivo contract research projects for the biopharmaceutical industry. Key customers are pharmaceutical companies, biotech firms, university hospitals and research institutes. The company does not run extensive in-house R&D but develops novel assay systems collaboratively with clients and undertakes limited proprietary product development.
Forschung und Dienstleistung im Bereich der Arzneimittelentwicklung, insbesondere auf dem Gebiet der Proteinkinasen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 5186 (as of 28 October 2026)
| Name | Type | City |
|---|---|---|
| Sebastian Dempe | Geschäftsführer(in) | Karlsruhe |
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 5186 (as of 28 October 2026)
| Date | Event Type | Event |
|---|---|---|
| 08.09.2020 | Company Name Change | Reaction Biology Europe GmbH |
| 08.09.2020 | Business Purpose Update | Schreibfehler beim Gegenstand von Amts wegen berichtigt in: Forschung und Dienstleistung im Bereich der Arzneimittelentwicklung, insbesondere auf dem Gebiet der Proteinkinasen. |
| 08.09.2020 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 10.03.2006 | Share Capital Set | — | 51.000 DM |
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 5186 (as of 28 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€7.2M2 | -€21,047,388 | €26,527,499 | — |
| 2023 | Rohergebnis€8M2 | -€829,797 | €37,312,063 | — |
| 2022 | Rohergebnis€9.6M2 | €1,859,322 | €39,122,849 | — |
| 2021 | Rohergebnis€7.7M2 | €1,720,232 | €6,821,233 | — |
| 2020 | small company1 | €1,034,456 | €4,608,528 | — |
| 2019 | small company1 | -€605,345 | €3,150,522 | — |
| 2018 | small company1 | -€478,506 | €2,011,364 | — |
| 2017 | small company1 | — | €2,119,428 | — |
| 2016 | small company1 | — | €2,320,705 | — |
| 2015 | small company1 | — | €1,895,865 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 5186 (as of 28 October 2026)
ETHRIS GmbH
Planegg · Forschung und Entwicklung im Bereich Biotechnologie
CLIMATE ANALYTICS gGmbH
Berlin · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
DASGIP Information and Process Technology GmbH
Jülich · Forschung und Entwicklung im Bereich Biotechnologie
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €4,794,748 | 80.8% |
| Depreciation | €271,478 | 4.6% |
| Interest & Similar | €870,807 | 14.7% |
